Evidence map›Paper›PMID 42245797›Full record

ArticleResearch square2026

The development of Breast Apocrine Carcinoma (BAC) score that distinguishes breast and cutaneous apocrine carcinomas.

Kei Kawashima, Akimitsu Yamada, Eleanor A Fallon, Ryo Fujita, Mahato Sasamoto, Masanori Oshi, Kazutaka Narui, Hideyuki Ishikawa, Jotaro Harada, Yukie Yamaguchi and 4 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kei KawashimaRoswell Park Comprehensive Cancer Center.
Akimitsu YamadaYokohama City University Graduate School of Medicine.
Eleanor A FallonRoswell Park Comprehensive Cancer Center.
Ryo FujitaYokohama City University Graduate School of Medicine.
Mahato SasamotoYokohama City University Graduate School of Medicine.
Masanori OshiYokohama City University Graduate School of Medicine.
Kazutaka NaruiYokohama City University Medical Center.
Hideyuki IshikawaYokohama City University Graduate School of Medicine.
Jotaro HaradaYokohama City University Graduate School of Medicine.
Yukie YamaguchiYokohama City University Graduate School of Medicine.
Satoshi FujiiYokohama City University Graduate School of Medicine.
Takashi IshikawaYokohama City University Graduate School of Medicine.
Itaru EndoYokohama City University Graduate School of Medicine.
Kazuaki TakabeRoswell Park Comprehensive Cancer Center.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor ImmunityR01CA250412 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., EVANS, SHARON S · 2021 to 2025
$3.4M
Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast CancerR01CA287731 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI Scott I. Abrams, Jianmin Zhang · 2024 to 2026
$2.8M
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor TherapiesR37CA248018 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Anna Bianchi-Smiraglia · 2021 to 2026
$2.3M
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA250412NCI NIH HHS R01 CA287731NCI NIH HHS R37 CA248018
6 · The paper itself

Abstract

Background: Apocrine carcinoma (AC) is a rare cancer that arises either from cutaneous apocrine sweat glands (cutaneous AC) or as breast carcinoma with apocrine differentiation (breast AC). Differentiation between them is clinically critical because their management and outcomes differ significantly: breast AC is treated according to established breast cancer therapies, whereas cutaneous AC lacks standardized systemic treatment and often carries a poorer prognosis. A diagnostic challenge arises when AC occurs in the axilla, where both entities may arise, given their highly similar histology. Methods: In this study, we performed a retrospective multi-cohort transcriptomic analysis integrating institutional, multi-institutional, and publicly available datasets to characterize the molecular differences between breast and cutaneous AC, and developed a transcriptomic classifier using differentially expressed genes and a LASSO logistic regression model for tissue-of-origin classification. Results: Transcriptomic profiling revealed that breast ACs exhibited higher steroid hormone-related signaling and lower proliferative activity compared with cutaneous ACs, while immune-related features were largely comparable between the two tumor types. These findings suggest that, despite shared apocrine morphology, breast and cutaneous ACs retain distinct biological characteristics reflective of their tissue of origin. Building on this, we further developed a transcriptomic classifier, the Breast Apocrine Carcinoma (BAC) score, which accurately distinguished breast and cutaneous ACs, suggesting that these tumors retain distinct tissue-of-origin transcriptional signatures despite shared apocrine differentiation. Furthermore, application of the BAC score to tumors with unknown primary origin in the axillary region enabled estimation of tissue origin, highlighting its potential clinical utility in diagnostically challenging cases. Conclusion: Breast and cutaneous ACs exhibit distinct biological features despite shared apocrine morphology. The BAC score accurately distinguished tumors of breast and cutaneous origin, including within AC cohorts, highlighting the potential utility of transcriptomic profiling for improving their classification and diagnostic evaluation.

Indexed as

Breast apocrine carcinomacutaneous apocrine carcinomadifferentiationdiscrimination scoretranscriptome

Identifiers

PMID42245797
PMCPMC13232451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.